-5%
Improvent MDI is indicated for the management of chronic obstructive pulmonary disease (COPD) in patients who remain symptomatic on a single bronchodilator. It provides dual bronchodilation by combining beta-agonist and anticholinergic agents to relieve bronchospasm.
Improvent combines two distinct bronchodilators:
- Salbutamol, a short-acting β₂-adrenergic agonist, relaxes airway smooth muscles.
- Ipratropium Bromide, an anticholinergic, blocks acetylcholine at muscarinic receptors, reducing bronchial constriction.
Together, they deliver enhanced bronchodilation via complementary mechanisms. The inhaler uses an eco-friendly HFA propellant, avoiding ozone-depleting CFCs.
